Clinical trials: Moderate Plaque Psoriasis
Palmoplantar Psoriasis
A Study of Zasocitinib in Adults With Non-pustular Palmoplantar Psoriasis
Palmoplantar psoriasis (PPPsO) is a type of psoriasis that affects the palms of hands and soles of the feet. It can cause red, thick, scaly patches, and it is often associated with pain and itching.
- Trial name
- NCT07752108
- Testing
- Zasocitinib
- Volunteers
- 40 people
- Sponsor
- Takeda
Parapsoriasis, Healthy Volunteers
Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis
To evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of CC-90005 in healthy subjects and subjects with moderate to severe plaque-type psoriasis.
- Trial name
- NCT02502188
- Testing
- CC-90005
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Celgene
Moderate to Severe Chronic Plaque Psoriasis
Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis
This is a randomized, double-blind, active-controlled, parallel-group, multicenter study designed to compare the efficacy, safety, immunogenicity, and PK(Pharmacokinetic) of Bmab 1200 with Stelara in adult patients with moderate…
- Trial name
- STELLAR-2 (NCT05335356)
- Testing
- Stelara, Bmab1200
- Where
- United States
- Volunteers
- 384 people
- Sponsor
- Biocon Biologics UK Ltd
Atopic Dermatitis, Plaque Psoriasis
Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis
This study is being conducted to provide data on efficacy, safety, tolerability and PK of PF-07038124 ointment versus vehicle control in the treatment of mild to moderate AD and mild to moderate plaque psoriasis.
- Trial name
- EMPORIA (NCT04664153)
- Testing
- PF-07038124 ointment, Vehicle ointment
- Where
- 29 sites in United States, Australia and 2 more
- Volunteers
- 104 people
- Sponsor
- Pfizer
Psoriasis
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis.
- Trial name
- VOYAGE 1 (NCT02207231)
- Testing
- Guselkumab 100 mg, Adalimumab
- Where
- 97 sites in United States, Australia and 8 more
- Volunteers
- 837 people
- Sponsor
- Janssen Research & Development, LLC
Plaque Psoriasis
Comparative Study of BAT2206 With Stelara® in Patients With Moderate to Severe Plaque Psoriasis
This study is a multicenter, randomized, double-blind, parallel-arm, Phase 3 study designed to compare efficacy, safety, immunogenicity, and PK of BAT2206 with Stelara in patients with moderate to severe plaque psoriasis.
- Trial name
- NCT04728360
- Testing
- BAT2206, Stelara (EU-sourced)
- Where
- China
- Volunteers
- 556 people
- Sponsor
- Bio-Thera Solutions
Moderate and Severe Plaque Psoriasis
A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis
This study is designed to provide efficacy and safety data of several doses of AEB071 so that the optimal dose and treatment duration can be chosen for testing in later studies in patients with plaque psoriasis (with a disease…
- Trial name
- NCT00885196
- Testing
- AEB071
- Where
- 40 sites in United States, Argentina and 7 more
- Volunteers
- 336 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
RESTORE: Raptiva® (Efalizumab) Evaluation of Safety and Treatment Optimization
RESTORE is an observational, open-label, multi-center, prospective, study enrolling Raptiva® (efalizumab) treated patients with moderate to severe chronic plaque psoriasis.
- Trial name
- RESTORE (NCT00402818)
- Where
- Canada
- Volunteers
- 294 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Psoriasis
Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Placebo-Controlled Study Comparing the Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects with Moderate to Severe Chronic Plaque Psoriasis
- Trial name
- CHAMPION (NCT00235820)
- Testing
- adalimumab, MTX
- Where
- United States
- Volunteers
- 271 people
- Sponsor
- Abbott
Psoriasis, Psoriatic Arthritis
Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis
This study will test the clinical effectiveness and safety of two orally administered doses of apremilast compared to placebo in Japanese patients with moderate-to-severe plaque-type psoriasis.
- Conditions
- Psoriasis, Psoriatic Arthritis, Psoriasis Arthropatica
- Trial name
- NCT01988103
- Testing
- Apremilast
- Where
- 56 sites in Japan
- Volunteers
- 254 people
- Sponsor
- Amgen
Psoriasis
HPP737 in Adult Patients With Moderate-to-severe Plaque Psoriasis.
The goal of this clinical trial is to learn if drug HPP737 works to treat moderate-to-severe plaque psoriasis in adults. It will also learn about the safety of drug HPP737.
- Trial name
- NCT07712705
- Testing
- HPP737
- Where
- 50 sites in China
- Volunteers
- 515 people
- Sponsor
- Newsoara Biopharma Co., Ltd.
Psoriasis
A Study to Assess Treatment Patterns, Clinical Outcomes and Healthcare Resource Utilization Among Adult Participants With Moderate-To-Severe Plaque Psoriasis
The purpose of this study is to achieve a better understanding of clinical characteristics, treatment patterns and clinical outcomes of participants with moderate-to-severe plaque psoriasis (PsO) as well as their unmet medical…
- Trial name
- NCT05547490
- Where
- 2 sites in China
- Volunteers
- 3,506 people
- Sponsor
- Bristol-Myers Squibb
Plaque Psoriasis
Evaluation of the Effectiveness of Secukinumab in Patients With Moderate to Severe Plaque Psoriasis
This study was a real-life study which was based on secondary data collection from the electronic or paper medical records from the Dermatology Clinics of the 14 University, Training \& Research Hospitals in Turkey.
- Trial name
- NCT05344482
- Testing
- Secukinumab
- Where
- United States
- Volunteers
- 277 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
The purpose of the study is to evaluate pharmacokinetic similarity, efficacy, safety and immunogenicity of multiple switches between ustekinumab and ABP 654 compared with continued use of ustekinumab in participants with moderate…
- Trial name
- NCT04761627
- Testing
- Ustekinumab, ABP 654
- Where
- 88 sites in United States, Canada and 6 more
- Volunteers
- 494 people
- Sponsor
- Amgen
Plaque Psoriasis
The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis
This is a Phase 2, multicenter, randomized, double-blinded, parallel dose group, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of 2 doses of TLL018 as therapy in approximately 90 participants with…
- Trial name
- NCT05772520
- Testing
- TLL018 tablets
- Where
- 35 sites in United States
- Volunteers
- 82 people
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Moderate to Severe Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis
A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis
The purpose of this study is to demonstrate the efficacy and safety of Certolizumab Pegol (CZP) in the treatment of moderate to severe chronic plaque Psoriasis (PSO) in Japanese subjects.
- Trial name
- NCT03051217
- Testing
- Certolizumab Pegol
- Where
- 33 sites in Japan
- Volunteers
- 127 people
- Sponsor
- UCB Biopharma S.P.R.L.
Psoriasis Vulgaris
A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With Psoriasis
This is a randomized, double-blind, placebo-controlled, multicentered phase III clinical study to evaluate the efficacy and safety of AK101 in the treatment of subjects with moderate-to-severe plaque psoriasis.
- Trial name
- NCT05120297
- Testing
- AK101
- Where
- 52 sites in China
- Volunteers
- 452 people
- Sponsor
- Akeso
Plaque Psoriasis
Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis
Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin.
- Trial name
- DREAM (NCT07039110)
- Where
- 84 sites in Canada, Czechia and 6 more
- Volunteers
- 700 people
- Sponsor
- AbbVie
Scalp Psoriasis
Clobetasol Propionate Spray Versus Vehicle Spray for the Management of Moderate to Severe Plaque Psoriasis of the Scalp
The primary objective of this study is to evaluate the safety and efficacy of clobetasol propionate spray versus vehicle spray for the management of moderate to severe plaque psoriasis of the scalp.
- Trial name
- NCT00881868
- Testing
- clobetasol propionate spray 0.05%, Vehicle spray
- Where
- 4 sites in United States
- Volunteers
- 81 people
- Sponsor
- Galderma R&D
Moderate and Severe Plaque Psoriasis
Safety and Efficacy of UC-MSCs in Patients With Plaque Psoriasis
This is a study in patients with moderate to severe chronic plaque psoriasis.All the participants will be randomized into three groups, high-dose UC-MSCs, low-dose UC-MSCs, or methotrexate group.This study is designed to prove…
- Trial name
- NCT03424629
- Testing
- Low-dose UC-MSCs, High-dose UC-MSCs, Methotrexate
- Where
- 2 sites in China
- Volunteers
- 57 people
- Sponsor
- Tianjin Ever Union Biotechnology Co., Ltd.